Literature DB >> 12452750

Acute cholestatic hepatitis associated with celecoxib.

Antonio Grieco1, Luca Miele, Andrea Giorgi, Ignazio M Civello, Giovanni Gasbarrini.   

Abstract

OBJECTIVE: To report a case of acute cholestatic hepatitis associated with the selective cyclooxygenase-2 inhibitor celecoxib. CASE
SUMMARY: A 41-year-old white man was hospitalized for jaundice after 2 doses of celecoxib 200 mg for pain associated with right-knee trauma. Laboratory workup showed hyperbilirubinemia, mildly elevated serum transaminase concentrations, and cholestasis. Abdominal imaging showed no dilation of the biliary tree. Histology showed cholestasis, with bile plugs in dilated bile canaliculi and a mild portal infiltrate that are highly suggestive of drug-induced cholestasis. DISCUSSION: This is the fourth report in the English-language literature describing cholestatic hepatitis temporally related to celecoxib use, the second supported by histologic findings typical of drug-induced cholestasis, and the first in a patient who denied use of alcoholic beverages and was taking no other drugs or herbal products at the time of the reaction. The Naranjo probability scale indicated that celecoxib was a probable cause of acute cholestatic hepatitis in this patient.
CONCLUSIONS: Cholestatic hepatitis is a well-recognized adverse effect of several drugs. Although celecoxib is considered to have a very low potential for hepatic toxicity, well-documented reports of adverse reactions can contribute significantly to the definition of more accurate safety profiles for new drugs introduced into clinical practice.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12452750     DOI: 10.1345/aph.1C110

Source DB:  PubMed          Journal:  Ann Pharmacother        ISSN: 1060-0280            Impact factor:   3.154


  7 in total

1.  Acute cholestatic hepatitis associated with long-term use of rofecoxib.

Authors:  Georgios I Papachristou; Anthony J Demetris; Mordechai Rabinovitz
Journal:  Dig Dis Sci       Date:  2004-03       Impact factor: 3.199

2.  Late-onset celecoxib-induced combined hepato-nephrotoxicity.

Authors:  James H Tabibian; Neshan Tabibian; David M Kaufman
Journal:  Br J Clin Pharmacol       Date:  2008-03-05       Impact factor: 4.335

3.  Rofecoxib-induced hepatotoxicity: a forgotten complication of the coxibs.

Authors:  Brian Yan; Yvette Leung; Stefan J Urbanski; Robert P Myers
Journal:  Can J Gastroenterol       Date:  2006-05       Impact factor: 3.522

4.  Celecoxib-induced cholestatic liver failure requiring orthotopic liver transplantation.

Authors:  Ihab I El Hajj; Shahid M Malik; Hany R Alwakeel; Obaid S Shaikh; Eizaburo Sasatomi; Hossam M Kandil
Journal:  World J Gastroenterol       Date:  2009-08-21       Impact factor: 5.742

Review 5.  Hepatotoxicity of Nonsteroidal Anti-Inflammatory Drugs: A Systematic Review of Randomized Controlled Trials.

Authors:  Pajaree Sriuttha; Buntitabhon Sirichanchuen; Unchalee Permsuwan
Journal:  Int J Hepatol       Date:  2018-01-15

6.  Celecoxib in arthritis: relative risk management profile and implications for patients.

Authors:  Gayle McKellar; Gurkirpal Singh
Journal:  Ther Clin Risk Manag       Date:  2009-11-18       Impact factor: 2.423

7.  Cholestatic hepatitis with small duct injury associated with celecoxib.

Authors:  Suresh Kumar Nayudu; Shanti Badipatla; Masooma Niazi; Bhavna Balar
Journal:  Case Rep Med       Date:  2013-06-05
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.